Testing the recovery and lifespan of treated red blood cells
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your blood counts and chemistry tests must be within normal limits, or if slightly off, your doctor must consider them not a problem.
- You cannot have a history of red blood cell disorders (like sickle cell disease, thalassemia, or G6PD deficiency) or autoimmune diseases that affect red blood cells.
- You cannot have taken medications that weaken the immune system (like prednisone) in the past 28 days.
- If you are able to have children, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special way to label your own red blood cells so doctors can track how long they survive in your body. It helps improve how we measure blood cell recovery after transfusion.
This study tests whether red blood cells treated with a special process (INTERCEPT) are safe and work well when given to people who have or don't have antibodies to these treated cells. It aims to understand if the treated cells can be used for transfusions in patients who have developed antibodies from previous transfusions.
This study collects and stores blood/blood-cell samples so researchers can use them for approved future studies. You would be tested for certain infections and health measurements to make sure the collection procedure is safe for you.
This trial tests whether using a measure of oxygen in your body can guide doctors on when to give you a blood transfusion. It may help avoid unnecessary transfusions while ensuring you get enough oxygen.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests a special way of preparing red blood cells for transfusion to see if it can help people with sickle cell anemia. If you already get regular transfusions, this study might offer a new option that could reduce complications.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.